Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Olatz Etxaniz"'
Autor:
Olga Romero-Clarà, Clara Madrid, Juan Carlos Pardo, Vicenç Ruiz de Porras, Olatz Etxaniz, Deborah Moreno-Alonso, Albert Font
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe high incidence and mortality rates of urothelial carcinoma mean it remains a significant global health concern. Its prevalence is notably pronounced in industrialized countries, with Spain registering one of the highest incidences in Eu
Externí odkaz:
https://doaj.org/article/ab827142f4f74762818a3ab766c2a1be
Autor:
Beatriz Cirauqui, Teresa Morán, Anna Estival, Vanesa Quiroga, Olatz Etxaniz, Carmen Balana, Matilde Navarro, Salvador Villà, Rosa Ballester, Mireia Margelí
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 130-138 (2020)
Germline mutations in TP53, a tumor suppressor gene, are involved in the development of Li-Fraumeni syndrome, a rare disorder that predisposes carriers to multiple tumors. TP53 mutations have been associated with resistance to treatment and poor prog
Externí odkaz:
https://doaj.org/article/a438a6d18bdc4096aa4eea1349a0fbcd
Autor:
Ovidio Fernández, Martín Lázaro-Quintela, Guillermo Crespo, Diego Soto de Prado, Álvaro Pinto, Laura Basterretxea, Alfonso Gómez de Liaño, Olatz Etxaniz, Sara Blasco, Clara Gabás-Rivera, Susana Aceituno, Virginia Palomar, Carlos Polanco-Sánchez
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
IntroductionThe purpose of this investigation was to explore patients’ and oncologists’ preferences for the characteristics of a pharmacological regimen for patients with advanced renal cell carcinoma (aRCC).Material and MethodsCross-sectional ob
Externí odkaz:
https://doaj.org/article/c8a4007ac3c748c9a9ecb0e664aafc7d
Autor:
María José Méndez-Vidal, Áurea Molina, Urbano Anido, Isabel Chirivella, Olatz Etxaniz, Eva Fernández-Parra, Marta Guix, Carolina Hernández, Julio Lambea, Álvaro Montesa, Álvaro Pinto, Silverio Ros, Enrique Gallardo
Publikováno v:
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-12 (2018)
Abstract Background Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinica
Externí odkaz:
https://doaj.org/article/722fb9affaea43eea50ec6bc3f06b33b
Autor:
Albert Font, Montserrat Domenech, Oscar Buisan, Hector Lopez, Andrea González, Olatz Etxaniz, Marta Matas, Xavier Elias, Maica Gomez, Mariona Figols, Judith Horneros, Juan Carlos Pardo, Lucia Notario, Vicenç Ruiz de Porras, Ignacio Perez, Joan Areal, Anna Esteve
Publikováno v:
World Journal of Urology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Purpose To develop a risk score based on a prognostic model and a nomogram integrating baseline clinicopathological variables to predict bladder cancer-specific survival (BCSS) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acdd52b04157bd81aa50446057dab6a6
https://doi.org/10.1007/s00345-022-04147-4
https://doi.org/10.1007/s00345-022-04147-4
Autor:
Ferrán, Losa, Isaura, Fernández, Olatz, Etxaniz, Alejandra, Giménez, Paula, Gomila, Lara, Iglesias, Federico, Longo, Esteban, Nogales, Antonio, Sánchez, Gemma, Soler
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 24(4)
Cancer of unknown primary site (CUP) is defined as a heterogeneous group of tumors that appear as metastases, and of which standard diagnostic work-up fails to identify the origin. It is considered a separate entity with a specific biology, and nowad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f63f1ab084378247e0938dbcc2952bda
https://pubmed.ncbi.nlm.nih.gov/35320504
https://pubmed.ncbi.nlm.nih.gov/35320504
Autor:
David J. Pinato, Sofia España, Eudald Felip, Margarita Romeo, Olatz Etxaniz, Anna Esteve, Ricard Mesia, Ainhoa Hernandez Gonzalez, Anna Pous
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
2544 Background: Cancer patients (pts) represent a high-risk population for severe COVID-19. Cancer-associated immunosuppression may hinder in the development of anti-SARS-CoV-2 antibodies. Methods: Data regarding baseline characteristics, COVID-19 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bde34fddeb9b27e1146eb4db3806f94
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2037
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2037
Autor:
Vicenç Ruiz de Porras, Olatz Etxaniz, Andrea Plaja, Oscar Buisan, Juan Carlos Pardo, Albert Font, Cristina Carrato
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 6271, p 6271 (2020)
International Journal of Molecular Sciences, Vol 21, Iss 6271, p 6271 (2020)
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the recommended treatment, with the highest level of evidence, for patients with muscle-invasive bladder cancer (MIBC). However, only a minority of patients receive this treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582d1cae87eeeecb6f182dac69c9862b
http://europepmc.org/articles/PMC7503307
http://europepmc.org/articles/PMC7503307
Autor:
Teresa Moran, Sofia España, Olatz Etxaniz, Marc Cucurull, Isabel Salinas, J.M. Velarde, Montserrat Marques-Pamies, Marta Domenech, Alejandra Pérez-Montes de Oca
Publikováno v:
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
Background: Immune-oncology agents (IOA) represent a turning point in the treatment of several solid tumors (ST). Although their toxicity compares favorably with other treatments, IOA associate immune-related adverse events (IR-AE), among which endoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efcba35cbb36a393d12c7b24a663fbc5
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3250
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3250
Autor:
Arroyo, Virginia Vallejos, Gracia, Ana Álvarez, Vives, Pol Servián, Moreno, Jordi Deportós, Llama, Sergio Ruiz, Lara, David Durany, Ulazia, Olatz Etxaniz, Pujantell, M. Teresa Salcedo, Carrasco, Sergio Lafuente, Aróztegui, Ana Paula Caresia, Calama, Joan Areal, Freixa, Salvador Villà, Freixa, Glòria Moragas
Publikováno v:
In Revista Española de Medicina Nuclear e Imagen Molecular May 2023 42 Supplement 1:S60-S61